会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明申请
    • CYCLOOXYGENASE- 2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE
    • CYCLOOXYGENASE-2选择性抑制剂,组合物和使用方法
    • WO2004010945A2
    • 2004-02-05
    • PCT/US2003/023605
    • 2003-07-29
    • NITROMED, INC.GARVEY, David, S.KHANAPURE, Subhash, P.RANATUNGE, Ramani, R.RICHARDSON, Stewart, K.SCHROEDER, Joseph, D.
    • GARVEY, David, S.KHANAPURE, Subhash, P.RANATUNGE, Ramani, R.RICHARDSON, Stewart, K.SCHROEDER, Joseph, D.
    • A61K
    • C07D213/55C07D213/50C07D231/12C07D231/14
    • The invention describes novel cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium­derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one COX-2 selective inhibitor, optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor, and/or, optionally, at least one therapeutic agent. The novel cyclooxygenase 2 selective inhibitors of the invention can be optionally nitrosated and/or nitrosylated. The invention also provides methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 selective inhibitors; for facilitating wound healing; for treating and/or preventing renal and/or respiratory toxicity; for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2; and for improving the cardiovascular profile of COX-2 selective inhibitors.
    • 本发明描述了新颖的环加氧酶2(COX-2)选择性抑制剂和包含至少一种环氧合酶2(COX-2)选择性抑制剂和任选地至少一种化合物的新型组合物, 或释放一氧化氮,刺激一氧化氮的内源性合成,提高内皮细胞和内皮细胞水平的内皮细胞衍生的舒张因子或是一氧化氮合酶的底物,和/或至少一种治疗剂。 本发明还提供了包含至少一种选择性抑制剂(任选亚硝化和/或亚硝基化)和任选地至少一种一氧化氮供体和/或任选地至少一种治疗剂的新型试剂盒。 本发明的新型环加氧酶2选择性抑制剂可以任选地亚硝化和/或亚硝基化。 本发明还提供治疗炎症,疼痛和发热的方法; 用于治疗和/或改善COX-2选择性抑制剂的胃肠道特性; 用于促进伤口愈合; 用于治疗和/或预防肾和/或呼吸毒性; 用于治疗和/或预防由环氧合酶-2水平升高引起的其他疾病; 并用于改善COX-2选择性抑制剂的心血管特征。
    • 8. 发明申请
    • SUBSTITUTED ARYL COMPOUNDS AS NOVEL CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE
    • 取代的芳基化合物作为新一代CYCLOOXYGENASE-2选择性抑制剂,组合物和使用方法
    • WO2002060378A2
    • 2002-08-08
    • PCT/US2001/048823
    • 2001-12-21
    • NITROMED, INC.KHANAPURE, Subhash, P.GARVEY, David, S.EARL, Richard, A.EZAWA, MaikoFANG, XinqinGASTON, Ricky, D.
    • KHANAPURE, Subhash, P.GARVEY, David, S.EARL, Richard, A.EZAWA, MaikoFANG, XinqinGASTON, Ricky, D.
    • A61K
    • C07D319/08A61K45/06C07D317/56C07D319/18C07D319/20C07D405/06
    • The invention describe novel substituted aryl compounds that are cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions comprising at elast one cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or, optionally, at least one therapeutic agent, such as, steroids, nonsterodal antiinflammatory compounds (NSAID), 5-lipoxygenase (5-LO) inhibitors, leukotriene B 4 (LTB 4 ) receptor antagonists, leukotriene A 4 (LTA 4 ) hydrolase inhibitors, 5-HT agonists, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitors, H 2 antagonists, antineoplastic agents, antiplatelet agents,thrombin inhibitors, thromboxane inhibitors, decongestants, diuretics, sedating or non-sedating anti-histamines, inducible nitric oxide synthase inhibitors, opioids, analgesics, Helicobacter pylori inhibitors, proton pump inhibitors, isoprostane inhibitors, and mixtures thereof. The invention also provides novel kits comprising at least one COX-2 selective inhibitor, and, optionally, at least one nitric oxide donor, and/or, optionally, at least one therapeutic agent. The novel cyclooxygenase 2 selective inhibitors of the invention can be optionally nitrosated and/or nitrosylated. The invention also provides methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 selective inhibitors; for facilitating wound healing; for treating and/or preventing renal toxicity or other toxicities; for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2; and for improving the cardiovascular profile of COX-2 selective inhibitors.
    • 本发明描述了作为环氧合酶2(COX-2)选择性抑制剂的新型取代的芳基化合物和包含弹性一环氧合酶2(COX-2)选择性抑制剂的新组合物,以及任选的至少一种捐赠,转移或释放硝酸的化合物 刺激内源性合成一氧化氮,提高内源性内皮水平的内源性松弛因子,或是一氧化氮合酶的底物,和/或任选的至少一种治疗剂,例如类固醇,非典型抗炎化合物(NSAID) ,5-脂氧合酶(5-LO)抑制剂,白三烯B4(LTB4)受体拮抗剂,白细胞三烯A4(LTA4)水解酶抑制剂,5-HT激动剂,3-羟基-3-甲基戊二酰辅酶A(HMG-CoA)抑制剂,H2拮抗剂 抗肿瘤剂,抗血小板药,凝血酶抑制剂,凝血恶烷抑制剂,减充血剂,利尿剂,镇静剂或非镇静抗组胺药,诱导型一氧化氮合酶抑制剂,阿片样物质,镇痛药 幽门螺杆菌抑制剂,质子泵抑制剂,异前列烷烷抑制剂及其混合物。 本发明还提供了包含至少一种COX-2选择性抑制剂和任选的至少一种一氧化氮供体,和/或任选的至少一种治疗剂的新型试剂盒。 本发明的新型环加氧酶2选择性抑制剂可以任选地亚硝化和/或亚硝化。 本发明还提供了治疗炎症,疼痛和发烧的方法; 用于治疗和/或改善COX-2选择性抑制剂的胃肠性质; 促进伤口愈合; 用于治疗和/或预防肾毒性或其他毒性; 用于治疗和/或预防由环氧合酶-2水平升高引起的其他疾病; 并用于改善COX-2选择性抑制剂的心血管外形。
    • 9. 发明授权
    • SUBSTITUTED ARYL COMPOUNDS AS NOVEL CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE
    • 取代作为一个新的芳基化合物,环氧合酶-2选择性抑制剂,组合物和使用方法
    • EP1406609B1
    • 2006-09-06
    • EP01998052.3
    • 2001-12-21
    • Nitromed, Inc.
    • KHANAPURE, Subhash, P.GARVEY, David, S.EARL, Richard, A.EZAWA, MaikoFANG, XinqinGASTON, Ricky, D.
    • A61K31/36C07D323/02
    • C07D319/08A61K45/06C07D317/56C07D319/18C07D319/20C07D405/06
    • The invention describes substituted aryl compounds that are cyclooxygenase 2 (COX-2) selective inhibitors and compositions comprising at elast one cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or, optionally, at least one therapeutic agent, such as, steroids, nonsterodal antiinflammatory compounds (NSAID), 5-lipoxygenase (5-LO) inhibitors, leukotriene B4 (LTB4) receptor antagonists, leukotriene A4 (LTA4) hydrolase inhibitors, 5-HT agonists, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitors, H2 antagonists, antineoplastic agents, antiplatelet agents,thrombin inhibitors, thromboxane inhibitors, decongestants, diuretics, sedating or non-sedating anti-histamines, inducible nitric oxide synthase inhibitors, opioids, analgesics, Helicobacter pylori inhibitors, proton pump inhibitors, isoprostane inhibitors, and mixtures thereof. The invention also provides novel kits comprising at least one COX-2 selective inhibitor, and, optionally, at least one nitric oxide donor, and/or, optionally, at least one therapeutic agent. The cyclooxygenase 2 selective inhibitors of the invention can be optionally nitrosated and/or nitrosylated. The invention also provides methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 selective inhibitors; for facilitating wound healing; for treating and/or preventing renal toxicity or other toxicities; for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2; and for improving the cardiovascular profile of COX-2 selective inhibitors.